Consun Pharmaceutical Group Limited reported a new share buyback executed on 03 June 2026. The company repurchased 127,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 14.02 to HKD 14.39, for an aggregate consideration of HKD 1.80 million. The volume-weighted average repurchase price was HKD 14.20 per share.

Following the transaction, issued shares (excluding treasury stock) decreased from 840.89 million to 840.76 million, a reduction of 0.0151%. Treasury shares rose to 789,000, while the total issued share capital (including treasury shares) remained unchanged at 841.55 million.

The buyback forms part of the mandate approved on 26 May 2026, which authorises the repurchase of up to 84.12 million shares. To date, 445,000 shares—equivalent to 0.529% of the issued share base on the mandate date—have been repurchased under this authority. Under Hong Kong listing rules, a moratorium on new share issues or treasury share sales is in place until 03 July 2026.